Appendix C. Data Extraction Tool for Part Two

Study identification **Unique ID** First author last name, year # authors ☐ Yes In there a methodologist listed as an author? □ No Journal Name Journal impact factor Is the journal classified as a methods journal? Does journal allow online supplement/appendix? ☐ Yes ☐ No ☐ Yes ☐ No Was there a published appendix or online Does the journal impose a word/table/figure limit? supplement? Word: ☐ Yes ☐ No Table/figure: ☐ Yes ☐ No ☐ Yes ☐ No If yes, what is the limit: Geographic location of # printed pages in main conduction? document **Funding Source:** ☐ Industry ☐ Government/Foundation ☐ Academia ☐ Other □Unknown Publication type: ☐ Full text journal article □Report (government, etc) □ Other Work affiliated with an agency? (ex. AHRQ, NICE, Cochrane, etc.) If yes, which agency: What terms were used to describe the indirect comparison? ☐ Network meta-analysis ☐ Mixed treatment comparison ☐ Multiple treatment comparison ☐ Other (i.e., simply by reference(s) used; exact terms): Study characteristics Study objective: Was it clear how the research question pertains to a network meta-analysis? ☐ Yes ☐ No ☐ Endocrinology ☐ Behavioral health ☐ Cardiology ☐ Oncology ☐ Pain Disease state evaluated ☐ Substance abuse ☐ Respiratory ☐ Infectious disease ☐ Rheumatology ☐ Gastroenterology ☐ Neurology ☐ Other: Methodological inclusion criteria? What network pattern was present? \square simple star \square star \square ladder \square closed loop □network with at least one closed loop Was a diagram displayed to show the network? ☐ Yes ☐ No #and type of interventions compared? (e.g device, procedure, pharmacologic, behavioral, other)

# of trials / #		
patients included		
in analysis:		
Methods Characteristics		
Method/model applied: ☐ Bayesian ☐ Frequentist Was traditional pair-wise meta-analysis also conducted? ☐ Yes ☐ No		
was traditional pair-wise meta-analysis also conducted: Tes No		
For Bayesian networks		
Model (all that apply):		
☐ Fixed-effects ☐ Random-effects ☐ Adjustment of model for studies with ≥3 treatments?		
□Evaluation on the dependence of treatment effect on a co-variate (adjustment) performed?		
Software used (including wrappers):		
Was the code published in the main manuscript? ☐ Yes ☐ No		
If no, was the code made available to the reader? ☐ Yes ☐ No		
If it was made available to the reader, in what format?		
□ online supplement □ referral to another website/source □email author □ other:		
If email author, were we able to obtain the code for this project? ☐ Yes ☐ No		
Was the raw data published in the main manuscript? ☐ Yes ☐ No		
If no, was the raw data made available to the reader? ☐ Yes ☐ No		
If it was made available to the reader, in what format?		
□ online supplement □ referral to another website/source □email author □ other:		
If amail author, were we able to obtain the raw data for this project? Ves No		
If email author, were we able to obtain the raw data for this project? ☐ Yes ☐ No Was Markov-chain Monte Carlo modeling used? ☐ Yes ☐ No		
If no, what sampling method was used?		
in no, what sampling method was osed.		
Were the starting value(s) reported (this can be obtained from provided code)? ☐ Yes ☐ No		
Number of chains:		
Number of iterations per chain:		
Number of iterations used for final results (after excluding burn-in):		
Were convergence statistics evaluated? ☐ Yes ☐ No		
Were prior distributions specified anywhere in the paper? (this can be obtained from provided code) ☐ Yes ☐ No		
If yes, what distribution was used for "D" and " σ " [often $N(0, 10^6)$ for D and Uniform(0, 2) for σ] (this can be obtained from provided code)?		
obtained from provided code):		
Were prior distributions justified in the paper? ☐ Yes ☐ No ☐ NA if not specified		
There prior distributions justified in the paper. In test in two in two in the specified		
Was sensitivity analysis performed based on prior distribution chosen?□ Yes □ No		
If yes, what was the distribution changed to?		
Was a graphical representation of the posterior distribution provided?		

☐ Yes ☐ No		
Do the authors rank order the efficacy and/or safety of different interventions compared?		
☐ Yes ☐ No	•	
Was model fit tested (i.e., sum deviation, residual devia	ition, DIC)?	
☐ Yes ☐ No	, ,	
If so, which was used?		
Was a description of how possible heterogeneity was evaluated (either qualitative or quantitative, e.g., I ² ,		
Cochrane Q, etc.) provided?		
☐ Yes ☐ No		
If yes, how?		
☐ traditional meta-analysis, how:	☐ network meta-analysis, how:	
traditional meta unarysis, now.	inctwork meta unarysis, now.	
Was a description of how possible inconsistency was ev	aluated (either qualitative or quantitative, e.g.	
Was a description of how possible inconsistency was evaluated (either qualitative or quantitative, e.g., comparison of direct evidence with the indirect evidence) provided?		
Yes No	e) provided:	
Does the analysis try to make a claim of:		
	PII Vas II Na	
Equivalence □ Yes □ No Non-inferiority?□ Yes □ No Was there an α priori decision rule/minimally important difference described?		
Yes □ No	difference described?	
Li fes Li No		
For Frequentist networks		
Model (all that apply):		
☐ Fixed-effects ☐ Random-effects		
☐ Evaluation on the dependence of treatment effect on a	co-variate (adjustment) performed?	
Software used:		
Was the raw data published in the main manuscript?□ Yes □ No		
If no, was the raw data made available to the reader? \square Yes \square No		
If it was made available to the reader, in what format?		
☐ online supplement ☐ referral to another website/sou	urce □email author □ other:	
Telefra to another website/soc	orce Demail action D other.	
If email author, were we able to obtain the raw data for th	is project? \square Vas \square No	
If email author, were we able to obtain the raw data for this project? ☐ Yes ☐ No Was a Linear Mixed Model Used?☐ Yes ☐ No		
was a Lilleal Mixed Model Osed: 11 165 11 110		
If no how was the model fit?		
If no, how was the model fit?		
How were studies weighted (inverse variance inverse same	onle size ets?)	
How were studies weighted (inverse variance, inverse sam	ipie size etc?):	
Was a description of how possible between situation of	reliented (either guelitative or guentitative or g	
Was a description of how possible heterogeneity was ex	raivated (either qualitative or quantitative, e.g., i ,	
Cochrane Q, etc.) provided?		
☐ Yes ☐ No		
15		
If yes, how?		
☐ traditional meta-analysis, how:	☐ network meta-analysis, how:	
Was a description of how possible inconsistency was ev		
comparison of direct evidence with the indirect evidenc	e) provided?	
☐ Yes ☐ No		

Does the analysis try to make a claim of:		
Equivalence ☐ Yes ☐ No Non-inferiority? ☐ Yes ☐ No		
Was there an α priori decision rule/minimally important difference described?		
☐ Yes ☐ No		
Posterior Distribution		
Outcome 1:		
☐ Binary ☐ Continuous ☐ Categorical non binary		
Is this outcome effect measure reported as mean or median data? Mean Median NR		
Format presented: ☐ Text ☐ Table ☐ Figure		
Effect size measured: ☐ Relative risk ☐ Odds ratio ☐ Risk difference ☐ Weighted-mean difference ☐ Other:		
Measure of variance: □ Credible interval, if yes □99% □95% □SD □ Other:		
Outcome 2:		
☐ Binary ☐ Continuous ☐ Categorical non binary		
Is this outcome effect measure reported as mean or median data? Mean Median NR		
Format presented: ☐ Text ☐ Table ☐ Figure		
Effect size measured: ☐ Relative risk ☐ Odds ratio ☐ Risk difference ☐ Weighted-mean difference		
□ Other:		
Measure of variance: ☐ Credible interval, if yes ☐99% ☐95% ☐SD ☐ Other:		
Outcome 3:		
☐ Binary ☐ Continuous ☐ Categorical non binary		
Is this outcome effect measure reported as mean or median data? ☐ Mean ☐ Median ☐ NR		
Format presented: ☐ Text ☐ Table ☐ Figure		
Effect size measured: ☐ Relative risk ☐ Odds ratio ☐ Risk difference ☐ Weighted-mean difference ☐ Other:		
Measure of variance: ☐ Credible interval, if yes ☐99% ☐95% ☐SD ☐ Other:		
Outcome 4:		
☐ Binary ☐ Continuous ☐ Categorical non binary		
Is this outcome effect measure reported as mean or median data? Mean Median NR		
Format presented: Text Table Figure		
Effect size measured: ☐ Relative risk ☐ Odds ratio ☐ Risk difference ☐ Weighted-mean difference		
☐ Other:		
Measure of variance: ☐ Credible interval, if yes ☐99% ☐95% ☐SD ☐ Other:		